Pharmaceutical Product Development Company Profile (NASDAQ:PPDI)

About Pharmaceutical Product Development (NASDAQ:PPDI)

Pharmaceutical Product Development logoPharmaceutical Product Development, Inc. is a global contract research organization providing drug discovery and development services. Its clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. Its development services include preclinical programs and Phase I through Phase IV clinical development services, as well as bioanalytical, cGMP, global central laboratory and vaccines and biologics laboratory services. The Company operates in two segments: Development and Discovery Sciences. In May 2009, the Company completed its disposition of its wholly owned subsidiary Piedmont Research Center, LLC. In December 2009, the Company completed its disposition of its wholly owned subsidiary PPD Biomarker Discovery Sciences, LLC. On April 2, 2009, the Company acquired Magen BioSciences, Inc. On April 21, 2009, the Company acquired AbC.R.O., Inc. On November 6, 2009, the Company acquired Excel PharmaStudies, Inc.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PPDI
  • CUSIP: N/A
  • Web: N/A
  • Trailing P/E Ratio: N/A
  • P/E Growth: N/A
  • Dividend Yield: 1.0%
Frequently Asked Questions for Pharmaceutical Product Development (NASDAQ:PPDI)

What is Pharmaceutical Product Development's stock symbol?

Pharmaceutical Product Development trades on the NASDAQ under the ticker symbol "PPDI."

Who are some of Pharmaceutical Product Development's key competitors?

How do I buy Pharmaceutical Product Development stock?

Shares of Pharmaceutical Product Development can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

MarketBeat Community Rating for Pharmaceutical Product Development (NASDAQ PPDI)
Community Ranking:  2.4 out of 5 ( )
Outperform Votes:  24 (Vote Outperform)
Underperform Votes:  25 (Vote Underperform)
Total Votes:  49
MarketBeat's community ratings are surveys of what our community members think about Pharmaceutical Product Development and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Pharmaceutical Product Development (NASDAQ:PPDI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Pharmaceutical Product Development (NASDAQ:PPDI)
No equities research coverage for this company has been tracked by


Earnings History for Pharmaceutical Product Development (NASDAQ:PPDI)
Earnings by Quarter for Pharmaceutical Product Development (NASDAQ:PPDI)
Earnings History by Quarter for Pharmaceutical Product Development (NASDAQ PPDI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2011$0.33$0.32ViewN/AView Earnings Details
2/8/2011$0.38$0.40ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Pharmaceutical Product Development (NASDAQ:PPDI)

No earnings estimates for this company have been tracked by


Dividend History for Pharmaceutical Product Development (NASDAQ:PPDI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Pharmaceutical Product Development (NASDAQ:PPDI)
No insider trades for this company have been tracked by


Headline Trends for Pharmaceutical Product Development (NASDAQ:PPDI)
Latest Headlines for Pharmaceutical Product Development (NASDAQ:PPDI)
DateHeadline logoGeneric Drugs Stock Performance Review -- Ironwood Pharma, Medicines Co., Supernus Pharma, and Pacira Pharma - June 12 at 8:02 AM logoRecro Pharma Appoints Ryan D. Lake as Senior Vice President of Finance and Chief Accounting Officer - June 6 at 8:08 AM logoAcurian Announces Hiring of Tom Privette to Lead Global Business Development - May 25 at 12:39 AM logoINC Research to merge with inVentiv in latest contract medical research deal - May 12 at 8:15 AM logoInnovus Pharma Launches ProstaGorx™ Product for Prostate Health Through its Beyond Human® Sales and Marketing Platform in the United States - May 1 at 11:23 AM logoLiveLeaf and Emery Pharma Enter into an R&D Alliance for Development of Next Generation Anti-Infective Drugs - April 13 at 7:09 PM logoPreveCeutical Signs Letter of Intent for Research & Development for Cannabinoid and Diabetes Products with UniQuest Pty Limited - April 13 at 9:35 AM logoBRIEF-Tetra Bio-Pharma, Intelgenx sign agreement for development, commercialization of Dronabinol XL tablet - April 3 at 9:08 AM logoBetter Buy: Bellicum Pharmaceuticals, Inc. vs. Kite Pharma - March 29 at 8:59 AM logoTrump chooses Gottlieb to run FDA; Pharma breathes sigh of relief - March 10 at 9:06 PM logoPharma says high prices fund drug development. This study says otherwise - March 8 at 9:07 PM logoLabCorp seeks to acquire N.C. clinical trials firm PPD, per report - March 4 at 7:19 PM logoPharmaceutical Analytical Testing Outsourcing Market Analysis By Services (Bioanalytical Testing, Method … - February 28 at 8:29 PM logoPPD Expands Nephrology Capabilities Through Collaboration with Frenova - February 22 at 9:23 AM logoQuark Pharmaceuticals Inc - Product Pipeline Review - 2016 - February 10 at 2:50 AM logoHeart Transplant Rejection - Pipeline Review, H2 2016 - Key Players Are Astellas Pharma Inc, Nekonal Sarl, Noxxon Pharma AG & Pelican Therapeutics - Research and Markets - February 8 at 2:49 AM logoImpel NeuroPharma Partners with Camargo Pharmaceutical Services for Development Programs - February 8 at 2:49 AM logoPharmaceutical Membrane Filtration Market by Product, Technique, Application - Global Forecast to 2021 - February 2 at 3:05 AM logoCanniMed Completes Initial Public Offering - December 29 at 9:00 AM logoAoxing Pharma Commences Production of Tilidine Hydrochloride Tablets - June 30 at 9:46 AM logoLannett To Co-Develop Generic Insulin Product For U.S. Market - April 23 at 8:42 AM logoPPD Strengthens Oncology Expertise for Drug Development - April 15 at 8:27 AM logoHalo Pharmaceutical and ExxPharma Therapeutics to Collaborate on the Development/Manufacturing of Products using Twin Screw Extrusion Technology - April 15 at 8:27 AM logoUPDATE - Actinium Announces Selection of Zevacor Pharma, Inc. for Clinical Production and Supply of Iomab-B for Pivotal Phase 3 SIERRA Trial - April 13 at 8:37 AM logoThis Triangle industry boasts 25% turnover and 7% raises - December 4 at 3:00 PM



Pharmaceutical Product Development (PPDI) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by Staff